DSpace Repository

Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents

Show simple item record

dc.contributor.author Pingaew R.
dc.contributor.author Saekee A.
dc.contributor.author Mandi P.
dc.contributor.author Nantasenamat C.
dc.contributor.author Prachayasittikul S.
dc.contributor.author Ruchirawat S.
dc.contributor.author Prachayasittikul V.
dc.date.accessioned 2021-04-05T03:32:26Z
dc.date.available 2021-04-05T03:32:26Z
dc.date.issued 2014
dc.identifier.issn 2235234
dc.identifier.other 2-s2.0-84905161366
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/13800
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905161366&doi=10.1016%2fj.ejmech.2014.07.087&partnerID=40&md5=4c490e6ea3dea932430f55e04459096e
dc.description.abstract A new series of chalcone-coumarin derivatives (9-19) linked by the 1,2,3-triazole ring were synthesized through the azide/alkyne dipolar cycloaddition. Hybrid molecules were evaluated for their cytotoxic activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) and antimalarial activity toward Plasmodium falciparum. Most of the synthesized hybrids, except for analogs 10 and 16, displayed cytotoxicity against MOLT-3 cell line without affecting normal cells. Analogs (10, 11, 16 and 18) exhibited higher inhibitory efficacy than the control drug, etoposide, in HepG2 cells. Significantly, the high cytotoxic potency of the hybrid 11 was shown to be non-toxic to normal cells. Interestingly, the chalcone-coumarin 18 was the most potent antimalarial compound affording IC50 value of 1.60 μM. Molecular docking suggested that the cytotoxicity of reported hybrids could be possibly due to their dual inhibition of α- and β-tubulins at GTP and colchicine binding sites, respectively. Furthermore, falcipain-2 was identified to be a plausible target site of the hybrids given their antimalarial potency. © 2014 Elsevier Masson SAS. All rights reserved.
dc.subject 4 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 4 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 4 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 4 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 4 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yll)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1 h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (4 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject 7 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one
dc.subject alpha tubulin
dc.subject antimalarial agent
dc.subject antineoplastic agent
dc.subject beta tubulin
dc.subject chalcone derivative
dc.subject coumarin derivative
dc.subject etoposide
dc.subject falcipain 2
dc.subject unclassified drug
dc.subject 1,2,3 triazole derivative
dc.subject 4 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 4 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 4 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 4 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 4 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [4 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject 7 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one
dc.subject antimalarial agent
dc.subject antineoplastic agent
dc.subject chalcone derivative
dc.subject colchicine
dc.subject coumarin derivative
dc.subject dihydroartemisinin
dc.subject doxorubicin
dc.subject ellipticine
dc.subject etoposide
dc.subject falcipain 2
dc.subject n [n (3 carboxyoxirane 2 carbonyl)leucyl]agmatine
dc.subject tubulin
dc.subject antimalarial agent
dc.subject antineoplastic agent
dc.subject chalcone
dc.subject coumarin
dc.subject coumarin derivative
dc.subject cysteine proteinase
dc.subject triazole derivative
dc.subject antimalarial activity
dc.subject antineoplastic activity
dc.subject article
dc.subject cancer cell line
dc.subject carbon nuclear magnetic resonance
dc.subject cycloaddition
dc.subject cytotoxicity
dc.subject drug structure
dc.subject drug synthesis
dc.subject HepG2 cell line
dc.subject human
dc.subject human cell
dc.subject molecular docking
dc.subject Plasmodium falciparum
dc.subject proton nuclear magnetic resonance
dc.subject A549 cell line
dc.subject AGMK cell line
dc.subject animal cell
dc.subject antimalarial activity
dc.subject Article
dc.subject cholangiocarcinoma cell line
dc.subject controlled study
dc.subject crystal structure
dc.subject drug binding site
dc.subject drug cytotoxicity
dc.subject drug potency
dc.subject drug screening
dc.subject drug synthesis
dc.subject hydrogen bond
dc.subject IC50
dc.subject leukemia cell line
dc.subject lymphatic leukemia
dc.subject molecular docking
dc.subject nonhuman
dc.subject structure activity relation
dc.subject Vero cell line
dc.subject chemistry
dc.subject drug effects
dc.subject metabolism
dc.subject protein conformation
dc.subject synthesis
dc.subject tumor cell line
dc.subject Antimalarials
dc.subject Antineoplastic Agents
dc.subject Cell Line, Tumor
dc.subject Chalcone
dc.subject Chemistry Techniques, Synthetic
dc.subject Coumarins
dc.subject Cysteine Endopeptidases
dc.subject Humans
dc.subject Molecular Docking Simulation
dc.subject Plasmodium falciparum
dc.subject Protein Conformation
dc.subject Triazoles
dc.subject Tubulin
dc.title Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation European Journal of Medicinal Chemistry. Vol 85, (2014), p.65-76
dc.identifier.doi 10.1016/j.ejmech.2014.07.087


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics